The global IVD infectious diseases market size was valued at USD 18.8 billion in 2018. It is likely to exhibit a CAGR of 6.7% from 2018 to 2026. Increasing external funding for research and development (R&D) activities and proactive government initiatives are among the primary growth stimulants for the market.
Key IVD techniques include immunochemistry assays, such as Enzyme-linked Immunosorbent Assay (ELISA) and immuno-agglutination. These assays are widely used in clinical laboratories and diagnostic centers for detecting infectious microorganisms such as bacteria and virus in patient samples.
Growing prevalence of target diseases, increasing health consciousness among people, and high demand for self-care medical devices are expected to stimulate the growth of the market through the forecast period. Moreover, introduction of novel products with improved sensitivity, speed, and user-friendliness is estimated to augment the adoption of IVD tests for infectious diseases over the coming years.
Technological advancements such as portable Real Time Polymerase Chain Reaction (qPCR) and increasing market penetration of technologies such as self-testing devices are key drivers in this therapeutic area. However, presence of ambiguous regulatory framework and high price of IVD diagnostic tests are inhibiting the growth of the market.
Reagents were the leading product segment in terms of revenue in 2018, majorly driven by their high usage rate. Increasing R&D initiatives pertaining to molecular diagnostic technologies and rising demand for point-of-care and self-test products are anticipated to support the dominance of the segment through 2026. The segment is projected to expand at a CAGR of 6.9% during the forecast period.
Analytical instruments are equipment and machines that assist in automating processes and combining reagents and samples. Commercial kits and robots assist in diagnosis through PCR for detecting and quantifying infectious microorganisms, blood antigens, and viral load.
In-Vitro Diagnostics (IVD) devices are applied in testing and diagnosis of several infectious diseases, such as HIV, Methicillin-resistant Staphylococcus aureus (MRSA), streptococcal infections, influenza, and hepatitis. HIV diagnostic tests held the largest share in the IVD infectious diseases market in 2018. The segment is primarily driven by high disease burden, low consumer awareness, and unmet clinical needs in developing countries.
Key players are updating range of test menus for their qPCR instruments by undertaking R&D initiatives for development of kits to curb emerging diseases or by entering into agreements with other kit manufacturing companies.
Based on technology, immunochemistry dominated the market in 2018. However, the segment is poised to lose its position to molecular diagnostics during the forecast period due to surging adoption and high demand for rapid, accurate, and sensitive devices. On contrary, microbiology is likely to witness moderate growth due to replacement of traditional methods by improved molecular diagnostic techniques.
Molecular diagnostics play an imperative role in the field of infectious disease testing by rendering fast and accurate results. In addition, growing prevalence of hospital-acquired infections and other infectious diseases is expected to propel the market during the forecast period. In addition, rising incidence of sexually transmitted diseases, such as HIV and HPV, is estimated to result in widened target population base.
Central laboratories led the market in terms of revenue in 2018. High volume of IVD tests are carried out in these laboratories. However, the Point-of-Care (PoC) segment is slated to exhibit a higher CAGR during the forecast period on account of increasing initiatives that aim at reducing hospital stays to curb healthcare spending and surging demand for rapid diagnosis near patient site.
High demand for bedside patient care, supported by flourishing home healthcare sector and increased market penetration of decentralized healthcare establishments, is one of the key drivers. Furthermore, burgeoning popularity of OTC or self-care products in emerging markets, such as India and China, improving healthcare infrastructure, and growing consumer awareness are working in favor of the overall market.
North America accounted for over 41.0% of the overall market value in 2018. It is anticipated to dominate the market through 2026, The growth is supported by presence of sophisticated healthcare infrastructure, favorable government initiatives, and high awareness levels of patients and practitioners.
Asia Pacific is projected to post the highest CAGR from 2018 to 2026, fueled by presence of high unmet medical needs, rapidly increasing government initiatives for communicable disease testing, and rising levels of healthcare expenditure in countries such as India and China.
Some of the key players in the market are Becton Dickinson; BioMerieux; Abbott Laboratories; Quidel Corporation; Alere Inc.; Orasure Technologies, Inc.; Hologic Inc.; Cepheid; Qiagen N.V.; Roche Diagnostics; Siemens Healthcare; and Bio-Rad Laboratories, Inc.
Increase in the number of strategic collaborations, aimed at boosting investments in R&D for novel therapeutics, has created ample growth opportunities in the market. Technological advancements in diagnostic platforms are poised to introduce upgraded versions of diagnosis and research tools for improved treatment of IVD infectious diseases.
|
Attribute |
Details |
|
Base year for estimation |
2018 |
|
Actual estimates/Historical data |
2014 - 2017 |
|
Forecast period |
2019 - 2026 |
|
Market representation |
Revenue in USD Million and CAGR from 2018 to 2026 |
|
Regional scope |
North America, Europe, Latin America, Asia Pacific, Middle East & Africa |
|
Country scope |
U.S., Canada, Germany, U.K., Spain, France, Italy, Brazil, Mexico, Argentina, Japan, China, India, South Korea, Australia, South Africa, Saudi Arabia, U.A.E. |
|
Report coverage |
Revenue forecast, competitive landscape, growth factors, and trends |
|
15% free customization scope (equivalent to 5 analysts working days) |
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of industry trends in each of the sub-segments from 2018 to 2026. For the purpose of this study, Grand View Research has segmented the global IVD infectious diseases market report based on product, technology, application, end use, and region:
Product Outlook (Revenue, USD Million, 2014 - 2026)
Instruments
Reagents
Software
Technology Outlook (Revenue, USD Million, 2014 - 2026)
Immunochemistry
Molecular Diagnostics
Microbiology
Others
Application Outlook (Revenue, USD Million, 2014 - 2026)
MRSA
Streptococcus
Clostridium difficile
VRE
CRE
Respiratory Virus
Candida
TB and Drug-resistant TB
Gastro-intestinal Panel Testing
Chlamydia
Gonorrhea
HPV
HIV
Hepatitis C
Hepatitis B
Others
End Use Outlook (Revenue, USD Million, 2014 - 2026)
Point of Care
Central Laboratories
Regional Outlook (Revenue, USD Million, 2014 - 2026)
North America
U.S.
Canada
Europe
U.K.
Germany
Spain
France
Italy
Latin America
Brazil
Mexico
Argentina
Asia Pacific
Japan
China
India
South Korea
Australia
Middle East & Africa
South Africa
Saudi Arabia
U.A.E.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
